RGNX - REGENXBIO Inc.
| Previous Close | 49.43 |
| Open | 49.59 |
| Bid | 51.96 x 800 |
| Ask | 51.98 x 1000 |
| Day's Range | 47.88 - 52.33 |
| 52 Week Range | 38.56 - 85.10 |
| Volume | 181,614 |
| Avg. Volume | 561,812 |
| Market Cap | 1.904B |
| Beta (3Y Monthly) | 1.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.05 |
| Earnings Date | Aug 6, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 82.67 |
- PR Newswire•6 days ago
REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference
ROCKVILLE, Md. , June 11, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Thomson Reuters StreetEvents•14 days ago
Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Regenxbio Inc Earnings Call
- American City Business Journals•20 days ago
FDA approves most expensive gene therapy ever — and here is its connection to Penn
The delivery of the Novartis gene therapy for a lethal disease has a strong tie to Penn researchers.
- Zacks•20 days ago
REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Motley Fool•24 days ago
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
- PR Newswire•24 days ago
REGENXBIO Announces First FDA Approval of a Gene Therapy Based on Its Proprietary NAV® Technology Platform
- FDA approval of Novartis' ZOLGENSMA for the treatment of pediatric patients with SMA marks the first regulatory approval based on REGENXBIO's NAV Technology - ZOLGENSMA validates the broad clinical applications ...
- PR Newswire•last month
REGENXBIO to Launch New Manufacturing Facility for NAV Technology-based AAV Gene Therapies
ROCKVILLE, Md., May 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced its plan to construct a current good manufacturing practice (cGMP) production facility, to be located in Rockville, Maryland. The new cGMP production facility will be integrated into REGENXBIO's previously announced new 132,000 square foot headquarters, for which construction is currently underway, and will allow for production of NAV Technology-based vectors at scales up to 2,000 liters using REGENXBIO's platform suspension cell culture process. The facility will be designed to meet global regulatory requirements and is expected to be operational in 2021.
- PR Newswire•last month
REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
ROCKVILLE, Md. , May 8, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
Motley Fool•last monthRegenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript
RGNX earnings call for the period ending March 31, 2019.
- Associated Press•last month
Regenxbio: 1Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 89 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- PR Newswire•last month
REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md. , May 7, 2019 /PRNewswire/ -- Reports positive interim update from RGX-314 Phase I/IIa trial for wet AMD in Cohort 3 over one year Announces new IND submission for RGX-314 for a Phase II ...
- Insider Monkey•2 months ago
Is Regenxbio Inc (RGNX) A Good Stock To Buy?
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]
- PR Newswire•2 months ago
REGENXBIO to Host Conference Call on May 7 to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , April 30, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Investor's Business Daily•2 months ago
A Second Baby Died In A Gene Therapy Study — Slugging This Biotech Stock
A second baby reportedly died in a study of Novartis' gene therapy, Zolgensma — sending shares of biotech Regenxbio into free fall Monday. Regenxbio lost nearly 8% by the closing bell.
- Motley Fool•2 months ago
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
- Simply Wall St.•2 months ago
Did The Underlying Business Drive REGENXBIO's (NASDAQ:RGNX) Lovely 384% Share Price Gain?
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. F...
- PR Newswire•2 months ago
REGENXBIO Appoints Dr. Steve Pakola as Chief Medical Officer
ROCKVILLE, Md., April 17, 2019 /PRNewswire/ -- REGENXBIO Inc. (RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced the appointment of Steve Pakola, M.D., as its Senior Vice President and Chief Medical Officer. Dr. Pakola will report to Kenneth T. Mills, REGENXBIO's President and Chief Executive Officer.
- PR Newswire•2 months ago
REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2019 Annual Meeting
ROCKVILLE, Md. , April 15, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Zacks•2 months ago
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- Motley Fool•2 months ago
3 Small-Cap Biotech Stocks to Watch Now
These under-the-radar stocks could be poised to make big moves in the coming months.
- GlobeNewswire•3 months ago
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Investopedia•3 months ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- Motley Fool•3 months ago
Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?
Roche and Biogen are spending big bucks on gene therapy biotech stocks.
- PR Newswire•3 months ago
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md. , March 6, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based ...
- Zacks•3 months ago
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
